2025-522404-24-01Not yet recruitingPhase 2/3
Test-Retest Evaluation of [18F]F-AraG in Lung Tumors (TREAT)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 27 Jan 2026
Brief summary (registry, in English)
To measure the variability in tumor and organ uptake between two, closely obtained, [18F]F-AraG PET scans.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 7 (estimated)
- First submitted
- 24 Sept 2025
- Start date
- 1 Oct 2025
- Lead sponsor
- Amsterdam UMC Stichting
- Diseases
- Lung cancer
- EU CT number
- 2025-522404-24-01
What you commit to
- Study type: Interventional · Phase 2/3
- Planned participants: 7
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with confirmed lung cancer who have at least one tumour of 2 cm or larger. Each person has two close-together PET scans with [18F]F-AraG.
- Age
- Above 18 years
- Sex
- All sexes can join.
- Disease stage
- Lung cancer confirmed by tissue examination. At least 1 lesion of ≥2cm. Disease must be measurable by RECIST 1.1.
- Earlier treatment
- Cannot be on active immunomodulatory treatment. Cannot have needed systemic corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medicines within 14 days of day 0.
Main reasons for not taking part
- Active immunomodulatory treatment
- Systemic corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medicines within 14 days of day 0
- Psychiatric or substance abuse disorders that would interfere with cooperation with the trial
- Pregnant or breastfeeding, or expecting to conceive during the trial
Read by machine on 9 Nov 2026.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients on active immunomodulatory treatment 2. Patients with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of day 0. Inhaled or topical steroids, and adrenal replacement steroid >10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease. 3. Psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. 4. Patient is pregnant or breastfeeding or expecting to conceive within the projected duration of the trial.
Who the study is looking for
- Histologically confirmed lung cancer 2. At least 1 lesion with size of ≥2cm 3. Willing and able to provide written informed consent for the trial 4. Above 18 years of age on day of signing informed consent 5. Have measurable disease based on RECIST 1.1
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Amsterdam UMC Stichting | Amsterdam | Netherlands | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.